Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.45 |
| ▸ | GRM1 | Q13255 | 9/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7584614 | 0.77 | CYP3A4 (0.70) | CYP3A4NFKB1PMP22MEN1KMT2A | |
| SCHEMBL3825244 | 0.76 | CYP3A4 (0.68) | CYP3A4NFKB1PMP22MEN1KMT2A | |
| SCHEMBL3435311 | 0.74 | CYP3A4 (0.66) | CYP3A4NFKB1PMP22MEN1KMT2A | |
| SCHEMBL6680554 | 0.74 | MEN1 (0.71) | CYP3A4NFKB1PMP22MEN1KMT2A | |
| SCHEMBL31680519 | 0.74 | CYP3A4 (1.00) | CYP3A4NFKB1PMP22MEN1KMT2A | |
| SCHEMBL1322530 | 0.74 | CYP3A4 (1.00) | CYP3A4NFKB1PMP22MEN1KMT2A | |
| SCHEMBL2549717 | 0.73 | MEN1 (0.73) | CYP3A4NFKB1PMP22MEN1KMT2A | |
| SCHEMBL21538459 | 0.72 | ESR2 (0.36) | CYP3A4NFKB1PMP22MEN1KMT2A | |
| SCHEMBL9235862 | 0.71 | SCN2A (0.68) | CYP3A4NFKB1PMP22MEN1KMT2A | |
| SCHEMBL11864526 | 0.70 | CYP3A4 (0.59) | CYP3A4NFKB1PMP22MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567477-B1 | SUBSTITUTED AMINO PHENYLACETIC ACIDS, DERIVATIVES THEREOF, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | NOVARTIS AG (CH) | 2009-09-09 | — | — | EP | disclosed |
| EP-2090566-A2 | Certain phenylacetic acids and derivatives | Novartis AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-7202364-B2 | Certain phenylacetic acids and derivatives | NOVARTIS, AG (CH) | 2007-04-10 | — | — | US | disclosed |
| CN-1729157-A | Substituted amino phenylacetic acids, derivatives thereof, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors | NOVARTIS AG (CH) | 2006-02-01 | — | — | CN | disclosed |
| US-20040132769-A1 | Certain phenylacetic acids and derivatives | NOVARTIS AG (CH) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132769-A1 | Certain phenylacetic acids and derivatives | CYP2A6, HCAR2, CYP2B6 | CYP3A4 169/4885NFKB1 1947/4885PMP22 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.